Biological sample collection to advance research and treatment: a Fight Osteosarcoma Through European Research (FOSTER) and Euro Ewing Consortium (EEC) statement

Darrell Green, Roelof van Ewijk, Elisa Tirtei, Dimosthenis Andreou, Fredrik Baecklund, Daniel Baumhoer, Stefan S. Bielack, Rajesh Botchu, Kjetil Boye, Bernadette Brennan, Michael Capra, Lucia Cottone, Uta Dirksen, Franca Fagioli, Natalia Fernandez, Adrienne M. Flanagan, Marco Gambarotti, Nathalie Gaspar, Hans Gelderblom, Craig GerrandAnne Gomez-Mascard, Jendrik Hardes, Stefanie Hecker-Nolting, Edita Kabickova, Leo Kager, Jukka Kanerva, Lennart Kester, Marieke Lydia Kuijjer, Valérie Laurence, Cyril Lervat, Antonin Marchais, Perrine Marec-Berard, Cristina Mendes, Johannes H. M. Merks, Benjamin Ory, Emanuela Palmerini, Pan Pantziarka, Evgenia Papakonstantinou, Sophie Piperno-Neumann, Anna Raciborska, Elizabeth A. Roundhill, Vilma Rutkauskaite, Akmal Safwat, Katia Scotlandi, Eric Staals, Sandra J. Strauss, Didier Surdez, Gwen Sys, Marie-Dominique Tabone, Maud Toulmonde, Claudia Valverde, Michiel van de Sande, Klaus Wörtler, Quentin Campbell-Hewson, Martin G. McCabe, Michaela Nathrath

Research output: Contribution to journalArticlepeer-review

1 Downloads (Pure)


Osteosarcoma and Ewing sarcoma are bone tumours mostly diagnosed in children, adolescents and young adults. Despite multi-modal therapy combining multi-agent chemotherapy with local therapy, morbidity is high and survival rates remain low, especially in the metastatic disease setting. Trials investigating targeted therapies and immunotherapies have not been ground-breaking. A greater understanding of biological subgroups, the role of the tumour immune microenvironment, factors that promote metastasis and clinical biomarkers of prognosis and drug response are required to make progress. A prerequisite to achieve desired success is a thorough, systematic and clinically linked biological analysis of patient samples but disease rarity and tissue processing challenges such as logistics and infrastructure have contributed to a lack of relevant samples for clinical care and research. There is a need for a Europe-wide framework to be implemented for the adequate and minimal sampling, processing, storage and analysis of patient samples. Two international panels of scientists, clinicians and patient and parent advocates have formed the Fight Osteosarcoma Through European Research (FOSTER) consortium and the Euro Ewing Consortium (EEC). The consortia shared their expertise and institutional practices to formulate new guidelines. We report new reference standards for adequate and minimally required sampling (e.g. time points, diagnostic samples, liquid biopsy tubes), handling and biobanking to enable advanced biological studies in bone sarcoma. We describe standards for analysis and annotation to drive collaboration and data harmonisation with practical, legal and ethical considerations. This position paper provides comprehensive guidelines that should become the new standards of care that will accelerate scientific progress, promote collaboration and improve outcomes.
Original languageEnglish
JournalClinical Cancer Research
Early online date13 Jun 2024
Publication statusE-pub ahead of print - 13 Jun 2024

Cite this